Become Affiliate

PepFlow

Download

The Photoprotection Analog

Melanotan I

Melanotan I is afamelanotide, a synthetic alpha-MSH analog and melanocortin agonist. Scenesse is a prescription subcutaneous implant for erythropoietic protoporphyria.

Skin appearance
TierB
EvidenceStrong
SafetyWell-Studied
FDA statusApproved
Last reviewed October 25, 2026 37 citations How to read these labels

What is Melanotan I?

Melanotan I is afamelanotide, a synthetic alpha-MSH analog and melanocortin agonist. Scenesse is a prescription subcutaneous implant for erythropoietic protoporphyria.[1][2][3]

Its high-confidence use is photoprotection in EPP, where increased eumelanin helps patients tolerate light exposure better.[1][2][3]

Melanotan I is distinct from Melanotan II. Afamelanotide has a regulated implant product and disease indication; Melanotan II is an unapproved tanning peptide with broader receptor activity.[1][2][3]

What Melanotan I is investigated for

Melanotan I evidence is grouped by practical use case and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

EPP photoprotection

Injectable

82%Strong

EPP photoprotection is the high-confidence Melanotan I/afamelanotide indication.[1][14][2]

Human evidence

FDA labeling and pivotal human trials support afamelanotide implant use for EPP photoprotection.[1][14][2]

Animal / mechanistic evidence

The photoprotective rationale follows alpha-MSH melanocortin activity and eumelanin induction.[1][14][2]

Vitiligo repigmentation with phototherapy

Injectable

58%Emerging

Vitiligo repigmentation is human-studied but separate from approved EPP photoprotection.[34]

Human evidence

A randomized multicenter trial evaluated afamelanotide with narrowband UV-B phototherapy for nonsegmental vitiligo.[34]

Animal / mechanistic evidence

The rationale is melanocortin-driven pigmentation combined with phototherapy-induced repigmentation.[34]

UV-free tanning and photoprotection

Injectable

56%Emerging

Pigmentation and tanning should be lower confidence than EPP and must not imply cosmetic approval.[4][7][3]

Human evidence

Human afamelanotide phototoxicity and photoprotection studies support pigmentation discussion, but cosmetic tanning is not the same as EPP treatment.[4][7][3]

Animal / mechanistic evidence

Melanocortin receptor activation supports eumelanin and photoprotection mechanisms.[4][7][3]

Acute stroke neuroprotection

Injectable

35%Preliminary

Acute stroke neuroprotection is human-studied at feasibility level, not an established stroke treatment.[18]

Human evidence

A small open-label feasibility and safety study evaluated afamelanotide in acute stroke patients; it was not definitive efficacy evidence.[18]

Animal / mechanistic evidence

The stroke rationale is melanocortin-related neuroprotection and vascular biology, separate from EPP photoprotection.[18]

Skin DNA-repair biology

Injectable

30%Limited

DNA-repair biology helps explain photoprotection interest, but it should not be written as proven skin-cancer prevention or cosmetic sunscreen replacement.[19][14]

Human evidence

Clinical photoprotection evidence exists for EPP, but DNA-repair enhancement itself is not established as a separate human clinical endpoint.[1][14]

Animal / mechanistic evidence

MC1R and alpha-MSH literature supports reduced UV-induced DNA damage and repair-pathway activation in skin models.[19][20]

Evidence snapshot

82%

Human evidence

Strong

FDA labeling and clinical trials support afamelanotide implant use for EPP photoprotection.[1][2][3]

34%

Animal / preclinical

Limited

MC1R-driven eumelanin production directly supports the photoprotection mechanism.[1][2][3]

82%

Mechanism support

Strong

Afamelanotide activates melanocortin-1 receptors on melanocytes, increasing eumelanin production. In EPP, that pigment response can improve photoprotection.[1][2][3]

Forms & administration

Afamelanotide is supplied as the approved Scenesse implant for erythropoietic protoporphyria, placed by a trained healthcare professional every two calendar months. Its product and schedule differ from unapproved Melanotan I tanning vials and self-injection protocols.[14][15][1]

Injectable

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Approved afamelanotide treatment uses a 16 mg implant. Unapproved vial protocols commonly start at 250 mcg.[33][14][15][1]

Frequency

The implant is given every 2 months. Vial protocols use 1 dose daily.[14][15][1][33]

Timing Considerations

Implant timing follows the specialist treatment plan.[14][15][1][33]

Cycle Length

Implant treatment is ongoing. Vial protocols commonly run 4 weeks.[14][15][1][33]

What to expect

First 2 months

Subcutaneous afamelanotide implant treatment gradually increases pigmentation and light tolerance in the EPP treatment context.[1][2][3][14][15]

Months 3-6

Subcutaneous implant outcomes center on phototoxic symptoms, pain-free light exposure, outdoor activity, and dermatology skin checks.[1][2][3][14][15]

After stopping

Pigmentation and photoprotection gradually fade after subcutaneous afamelanotide implants stop as exposure and skin turnover change.[1][2][3][14][15]

Safety profile

Melanotan I safety should separate SCENESSE implant labeling for EPP from non-label tanning use. Skin monitoring, implant-site reactions, nausea, fatigue, and pigmentation matter.[14][1]

Common side effects

Cautions

What we don't know

Cosmetic tanning protocols and self-injected products are separate from the SCENESSE EPP label and have different safety uncertainty.[14][1]

Who Melanotan I is not for

Route-specific avoid and medical-review notes:

  • Use outside label without clinician oversight

    Use outside label without clinician oversight warrants medical review or avoidance for Melanotan I.[14][1][2][3]

  • Concerning moles without dermatology review

    Concerning moles without dermatology review warrants medical review or avoidance for Melanotan I.[14][1][2][3]

  • Pregnancy or breastfeeding unless specifically supervised

    Pregnancy or breastfeeding unless specifically supervised warrants medical review or avoidance for Melanotan I.[14][1][2][3]

Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

Theoretical interactions

  • Photosensitizers / UV exposure

    Photosensitizing drugs and intentional UV tanning can change burn, pigmentation, and skin-monitoring decisions; this is a route-specific caution.[14][1]

  • Melanocortin tanning products

    Melanotan II, bremelanotide, or other melanocortin products can stack pigmentation, nausea, and vascular effects; this is a theoretical pathway caution.[14][1]

  • Immunosuppressants / skin risk

    Immunosuppressants or therapies that raise skin-cancer risk can change dermatology monitoring decisions; this is a route-specific caution.[14][1]

Pairing notes

Not recommended with

Melanotan II: overlapping pigmentation effectsInjectable

Melanotan I and Melanotan II both activate melanocortin pathways that increase pigmentation. Using both duplicates melanocortin exposure, while Melanotan II also adds nausea, sexual-response, and poorly characterized systemic effects.[33][35][36]

PT-141: overlapping melanocortin signalingInjectable

Melanotan I and PT-141 both activate melanocortin receptors, although they are used for different effects. Combined exposure has no validated benefit and can make pigmentation, nausea, and systemic effects harder to attribute.[14][37]

How it works

Melanotan I, clinically developed as afamelanotide, activates melanocortin-1 receptors on melanocytes and increases eumelanin production. In plain terms, it darkens pigment in a way that can improve photoprotection for erythropoietic protoporphyria patients.[1][2][3]

Delivery and indication define the mechanism. The approved afamelanotide context uses an implant under medical supervision with phototoxic disease monitoring; that is not equivalent to casual tanning injections, research-market vials, or unsupervised pigment manipulation. The route, implant format, and disease context are what make the pharmacology clinically interpretable.[1][2][3]

Research gaps & open questions

What the current literature has not yet settled about Melanotan I:

01

Trials need to show whether afamelanotide or Melanotan I is useful for tanning, skin disease, or other uses outside erythropoietic protoporphyria (EPP).[1][2][3]

02

Long-term studies outside approved EPP care should track persistent pigmentation, changes in moles, and other skin outcomes.[1][2][3]

03

Research and product labeling need to clearly distinguish approved afamelanotide implants from unapproved Melanotan I and Melanotan II products, which are not interchangeable.[1][2][3]

Common questions

Is Melanotan I FDA-approved?

Yes. Afamelanotide is FDA-approved as SCENESSE for EPP photoprotection; that is not approval for cosmetic tanning.[15][16][14][1]

Is Melanotan I the same as Melanotan II?

No. Afamelanotide has a disease-specific approved implant product; Melanotan II is an unapproved systemic tanning peptide.[15][16][14][1]

Is it approved for cosmetic tanning?

No. Melanotan I is not FDA-approved for cosmetic tanning; SCENESSE is approved for EPP photoprotection.[15][16][14][1]

Myths & misconceptions

Myth

Scenesse approval means melanotan is approved for tanning.

Reality

Approval is for EPP photoprotection, not cosmetic tanning.[1][2][3]

Myth

All melanotan peptides are interchangeable.

Reality

Receptor selectivity, route, evidence, and regulatory status differ.[1][2][3]

History & discovery

Melanotan I developed into afamelanotide, an alpha-MSH analog aimed at increasing eumelanin and photoprotection. Its history is disease-specific rather than a general tanning-product story. That distinction keeps the origin story tied to evidence strength, route, and product identity rather than broad clinical certainty.[1][2][3][14]

Clinical studies in erythropoietic protoporphyria tested whether afamelanotide could increase pain-free light exposure. That established photoprotection as the main outcome, not cosmetic tanning.[1][2][3][14]

FDA approval of SCENESSE created a supervised implant precedent for adult EPP patients. The milestone narrowed the route and indication, separating afamelanotide from unapproved tanning injections.[1][2][3][14]

Published research37 citations

Show citationsHide citations

PepFlow library coverage

Keep It Organized

Stay consistent with your skin-care goals.

Use PepFlow to record your Melanotan I protocol, set reminders for your own schedule, and review your history.

Download on the App StoreGet it on Google Play
PepFlow calendar on Thursday, April 9, listing BPC-157 at 10:00 and GHK-CU at 18:00